By Erin Marie Daly ( February 23, 2009, 12:00 AM EST) -- The epilepsy drug zonisamide — marketed under the brand name Zonegran by Eisai Co. Ltd. and sold in generic form by Teva Pharmaceutical Industries Ltd., Mylan Inc., Novartis AG's Sandoz unit and Watson Pharmaceuticals Inc. — has come under fire by federal health regulators, who warned Monday the medication can cause a serious blood disorder known as metabolic acidosis in some patients....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.